Announcements Trials
Browse Landscape

Phase

Phase 2 36Phase 3 5Phase 1 5Phase 1/2 4Phase NA 3Phase 4 1Phase 2/3 1

Status

Recruiting 3Unknown 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Non Small Cell Lung Cancer NSCLC 1Neoplasm, Residual 1NSCLC 1Advanced Lung Cancer 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × aflutinib × Clear all
NCT07229599 2025-11-17

A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer

Minghui Pharmaceutical (Hangzhou) Ltd

Phase 1/2 Recruiting
300 enrolled
Thoracic

Advanced Lung Cancer

NCT07087223 2025-07-25

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

Peking University Cancer Hospital & Institute

Phase 1/2 Recruiting
42 enrolled
Thoracic

Non Small Cell Lung Cancer NSCLC

NCT05994131 2025-04-30

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

InxMed (Shanghai) Co., Ltd.

Phase 1/2 Recruiting
110 enrolled
Thoracic

NSCLC

NCT05079022 2021-10-15

ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

Peking University People's Hospital

Phase 1/2 Unknown
50 enrolled
Thoracic

Adenocarcinoma of Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡